Treating systemic prostate cancer: emerging drug targets and therapies
- 1 December 2000
- journal article
- Published by Informa Healthcare in Emerging Therapeutic Targets
- Vol. 4 (6), 751-763
- https://doi.org/10.1517/14728222.4.6.751
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Treatment of prostate cancer in vitro and in vivo with 2-5A-anti-telomerase RNA componentOncogene, 2000
- Dendritic Cells in Cancer ImmunotherapyAnnual Review of Immunology, 2000
- FOCAL INTRATUMORAL HETEROGENEITY FOR TELOMERASE ACTIVITY IN HUMAN PROSTATE CANCERJournal of Urology, 1999
- Phase II prostate cancer vaccine trial: Report of a study involving 37 patients with disease recurrence following primary treatmentThe Prostate, 1999
- Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: A phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic diseaseThe Prostate, 1999
- harakiri, a novel regulator of cell death, encodes a protein that activates apoptosis and interacts selectively with survival-promoting proteins Bcl-2 and Bcl-XLThe EMBO Journal, 1997
- A phase II trial of all- trans -retinoic acid in hormone-refractory prostate cancer: a clinical trial with detailed pharmacokinetic analysisCancer Chemotherapy and Pharmacology, 1997
- The Biologic Effects of C225, A Chimeric Monoclonal Antibody to the EGFR, on Human Prostate CarcinomaJournal of Immunotherapy, 1996
- Expression of human prostate-specific antigen (PSA) in a mouse tumor cell line reduces tumorigenicity and elicits PSA-specific cytotoxic T lymphocytesCancer Immunology, Immunotherapy, 1996
- Phase I study of phenylacetate administered twice daily to patients with cancerCancer, 1995